Tardy With This — But Here Is Where Pfizer Spent Its Q2 2022 ~$3.48 Million, In DC.

We didn’t mean for it to work out this way. We just got distracted. And then, frankly… we plain old… forgot.

But we noticed that on September 9, 2022, Pfizer had amended its disclosures. So being late… let us be… accurate. Grin.

Here it is, among other matters:

…Drug Pricing, Support of Biosimilars, Out-of-Pocket Costs, Rebate Reform, Vaccine Infrastructure/HR 3656 Excise Tax- S.3087, Antimicrobial Resistance/HR 3932/PASTEUR Act, COVID Relief Package/Appropriations, PDUFA….

Medicare Part D support for access to treatments for obesity, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, Government Negotiation in Medicare….

Comprehensive Corporate Tax Reform, International Tax Reform, OECD Profit Allocation, U.S. Manufacturing Credits, Build Back Better Act, Minimum Tax….

NAFTA/USMCA, Foreign Market Access issues (including IPR), International Supply Chain/Buy America – harmonize international drug manufacturing standards, Global Access to Medicines….

TRIPS Waiver, General IP Issues, Bayh-Dole March-In Rights….

Now you know. Sorry about the delay… smile.

नमस्ते